MX2016017177A - Use of the sodium cefoperazone for the treatment of chagas disease as an anti-trypanosoma cruzi agent. - Google Patents

Use of the sodium cefoperazone for the treatment of chagas disease as an anti-trypanosoma cruzi agent.

Info

Publication number
MX2016017177A
MX2016017177A MX2016017177A MX2016017177A MX2016017177A MX 2016017177 A MX2016017177 A MX 2016017177A MX 2016017177 A MX2016017177 A MX 2016017177A MX 2016017177 A MX2016017177 A MX 2016017177A MX 2016017177 A MX2016017177 A MX 2016017177A
Authority
MX
Mexico
Prior art keywords
agent
treatment
trypanosoma cruzi
chagas disease
sodium cefoperazone
Prior art date
Application number
MX2016017177A
Other languages
Spanish (es)
Inventor
Rivera Sánchez Gildardo
NOGUEDA TORRES Benjamín
Eduardo LARA RAMÍREZ Edgar
César López Cedillo Julio
Original Assignee
Inst Politecnico Nacional
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Politecnico Nacional filed Critical Inst Politecnico Nacional
Priority to MX2016017177A priority Critical patent/MX2016017177A/en
Publication of MX2016017177A publication Critical patent/MX2016017177A/en

Links

Classifications

    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of sodium cefoperazone with excellent selectivity to Trypanosoma cruzi, comprising sodium cefoperazone, as well as its pharmaceutically acceptable salts and its use in medicaments for treating human and mammals with Chagas disease or American trypanosomiasis.
MX2016017177A 2016-12-20 2016-12-20 Use of the sodium cefoperazone for the treatment of chagas disease as an anti-trypanosoma cruzi agent. MX2016017177A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MX2016017177A MX2016017177A (en) 2016-12-20 2016-12-20 Use of the sodium cefoperazone for the treatment of chagas disease as an anti-trypanosoma cruzi agent.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2016017177A MX2016017177A (en) 2016-12-20 2016-12-20 Use of the sodium cefoperazone for the treatment of chagas disease as an anti-trypanosoma cruzi agent.

Publications (1)

Publication Number Publication Date
MX2016017177A true MX2016017177A (en) 2018-06-19

Family

ID=63361801

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016017177A MX2016017177A (en) 2016-12-20 2016-12-20 Use of the sodium cefoperazone for the treatment of chagas disease as an anti-trypanosoma cruzi agent.

Country Status (1)

Country Link
MX (1) MX2016017177A (en)

Similar Documents

Publication Publication Date Title
MX2019009443A (en) Methods of treating influenza.
PH12015502773A1 (en) Methods for treating or preventing opthalmological conditions
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2021002321A (en) Novel methods.
MX2016015378A (en) Use of eribulin in the treatment of cancer.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
EA201692111A1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DANIRYXIN FOR TREATING INFECTIOUS DISEASES
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2016017177A (en) Use of the sodium cefoperazone for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
MX2016017175A (en) Use of sodium flucloxacillin for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
PH12016501975A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
MX2016017182A (en) Use of sodium piperacillin for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
EA201501130A1 (en) OPHTHALMOLOGIC PHARMACEUTICAL COMPOSITION
MX2016017197A (en) Use of sulfasalazine for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
MX2016017185A (en) Use of ketanserin tartrate for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
MX2016017183A (en) Use of doxazosin mesylate for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
MX2016017186A (en) Use of etofylline clofibrate for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
MX2017001766A (en) Use of sodium cefsulodine for the treatment of chagas disease as an anti-trypanosoma cruzi agent.
PH12016501127A1 (en) Adenosine a1 agonists as medicaments against renal diseases
CL2018002930A1 (en) (+) - azasetron for use in the treatment of ear disorders.
MX2016016018A (en) Use of terfenadine for the treatment of chagas disease as anti-trypanosoma cruzi agent.
MX2021006468A (en) Use of glipizide for treating chagas disease as an anti-trypanosoma cruzi agent.
MX2021006466A (en) Use of gliquidone for treating chagas disease as an anti-trypanosoma cruzi agent.
PH12016502107A1 (en) Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders